Bionano Genomics (NASDAQ: BNGO) Chief Medical Officer to step down

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Bionano Genomics, Inc. reported that its Chief Medical Officer, Alka Chaubey, Ph.D., has resigned. The resignation was submitted on June 2, 2026 and will be effective July 5, 2026. The company is incorporated in Delaware and its common stock trades on the Nasdaq Capital Market under the symbol BNGO.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Key Figures

Resignation notice date: June 2, 2026 Resignation effective date: July 5, 2026 Par value per share: $0.0001 per share +1 more

4 metrics

Resignation notice date June 2, 2026 Date CMO resignation was submitted

Resignation effective date July 5, 2026 Date CMO role ends

Par value per share $0.0001 per share Common stock par value

Company phone number (858) 888-7600 Principal executive office phone

Key Terms

Emerging growth company, Chief Medical Officer, Interim Chief Executive Officer, Exchange Act

4 terms

Emerging growth company regulatory

"Emerging growth company Departure of Chief Medical Officer"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

Chief Medical Officer financial

"June 2, 2026, Alka Chaubey, Ph.D. resigned as Chief Medical Officer"

A chief medical officer is a senior executive responsible for overseeing the health and medical strategies within an organization, often in the healthcare or pharmaceutical sectors. They play a key role in guiding decisions related to medical research, product safety, and healthcare policies, which can impact a company's reputation and success. For investors, understanding the chief medical officer's role helps gauge how well a company manages medical risks and advances its healthcare goals.

Interim Chief Executive Officer financial

"Albert A. Luderer, Ph.D. Interim Chief Executive Officer"

Exchange Act regulatory

"Rule 12b-2 of the Securities Exchange Act of 1934"

A federal law that sets rules for trading securities on public exchanges, requiring companies and market participants to register, disclose regular financial information, and follow standards that promote honest, orderly markets. For investors, it matters because it creates transparency and legal protections—like stopping insider trading and ensuring timely company disclosures—so you can evaluate risks and rely on consistent rules much as players rely on a referee to keep a game fair.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Understanding 8-K Material Events →

06/05/2026 - 04:00 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 2, 2026

Bionano Genomics, Inc.

(Exact Name of Registrant as Specified in its Charter)

     Delaware

     001-38613

     26-1756290

     (State or Other Jurisdiction
of Incorporation)

     (Commission
File Number)

     (IRS Employer
Identification No.)

     9540 Towne Centre Drive, Suite 100
San Diego, California

     92121

     (Address of Principal Executive Offices)

     (Zip Code)

Registrant’s telephone number, including area code: (858) 888-7600

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.0001 par value per share	BNGO	The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


Item 5.02.	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Departure of Chief Medical Officer

On June 2, 2026, Alka Chaubey, Ph.D. resigned as Chief Medical Officer of Bionano Genomics, Inc. (the “Company”) effective July 5, 2026.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


	Bionano Genomics, Inc.

Date: June 5, 2026	By:	/s/ Albert A. Luderer, Ph.D.
		Albert A. Luderer, Ph.D.
		Interim Chief Executive Officer

Source: View Original Filing on SEC EDGAR

FAQ

What leadership change did Bionano Genomics (BNGO) disclose in this 8-K?

Bionano Genomics disclosed the resignation of its Chief Medical Officer. The filing states that Alka Chaubey, Ph.D. resigned from the Chief Medical Officer role, with an effective date of July 5, 2026, following notice provided on June 2, 2026.

When is Bionano Genomics Chief Medical Officer Alka Chaubey, Ph.D. leaving?

Alka Chaubey, Ph.D. will leave Bionano Genomics on July 5, 2026. According to the filing, she resigned as Chief Medical Officer on June 2, 2026, with her resignation scheduled to become effective in early July 2026.

What role does Albert A. Luderer, Ph.D. hold at Bionano Genomics (BNGO)?

Albert A. Luderer, Ph.D. serves as Interim Chief Executive Officer. He signed the report on behalf of Bionano Genomics, Inc., indicating his position as interim CEO at the time of the leadership change involving the Chief Medical Officer.

On which exchange is Bionano Genomics common stock listed and under what symbol?

Bionano Genomics common stock trades on the Nasdaq Capital Market as BNGO. The filing confirms that its common stock, with a par value of $0.0001 per share, is registered under the trading symbol BNGO on the Nasdaq Capital Market.

What type of company is Bionano Genomics under SEC definitions?

Bionano Genomics is identified as an emerging growth company. The filing references status under Rule 405 of Regulation C and Rule 12b-2 of the Exchange Act, indicating the company qualifies as an emerging growth company for SEC reporting purposes.

What is Bionano Genomics’ principal executive office address?

Bionano Genomics’ principal executive offices are in San Diego, California. The filing lists the address as 9540 Towne Centre Drive, Suite 100, San Diego, California 92121, which is the company’s main business location for executive operations.

Filing Exhibits & Attachments

1 document